Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer
Copyright © 2017 The Author(s). Published by Elsevier Inc. All rights reserved..
Cancer cells exhibit increased use of nutrients, including glucose and glutamine, to support the bioenergetic and biosynthetic demands of proliferation. We tested the small-molecule inhibitor of glutaminase CB-839 in combination with erlotinib on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) as a therapeutic strategy to simultaneously impair cancer glucose and glutamine utilization and thereby suppress tumor growth. Here, we show that CB-839 cooperates with erlotinib to drive energetic stress and activate the AMP-activated protein kinase (AMPK) pathway in EGFR (del19) lung tumors. Tumor cells undergo metabolic crisis and cell death, resulting in rapid tumor regression in vivo in mouse NSCLC xenografts. Consistently, positron emission tomography (PET) imaging with 18F-fluoro-2-deoxyglucose (18F-FDG) and 11C-glutamine (11C-Gln) of xenografts indicated reduced glucose and glutamine uptake in tumors following treatment with CB-839 + erlotinib. Therefore, PET imaging with 18F-FDG and 11C-Gln tracers can be used to non-invasively measure metabolic response to CB-839 and erlotinib combination therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Cell reports - 18(2017), 3 vom: 17. Jan., Seite 601-610 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Momcilovic, Milica [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.12.2017 Date Revised 17.10.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.celrep.2016.12.061 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM268118957 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM268118957 | ||
| 003 | DE-627 | ||
| 005 | 20231226193532.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.celrep.2016.12.061 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0893.xml |
| 035 | |a (DE-627)NLM268118957 | ||
| 035 | |a (NLM)28099841 | ||
| 035 | |a (PII)S2211-1247(16)31768-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Momcilovic, Milica |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.12.2017 | ||
| 500 | |a Date Revised 17.10.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2017 The Author(s). Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Cancer cells exhibit increased use of nutrients, including glucose and glutamine, to support the bioenergetic and biosynthetic demands of proliferation. We tested the small-molecule inhibitor of glutaminase CB-839 in combination with erlotinib on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) as a therapeutic strategy to simultaneously impair cancer glucose and glutamine utilization and thereby suppress tumor growth. Here, we show that CB-839 cooperates with erlotinib to drive energetic stress and activate the AMP-activated protein kinase (AMPK) pathway in EGFR (del19) lung tumors. Tumor cells undergo metabolic crisis and cell death, resulting in rapid tumor regression in vivo in mouse NSCLC xenografts. Consistently, positron emission tomography (PET) imaging with 18F-fluoro-2-deoxyglucose (18F-FDG) and 11C-glutamine (11C-Gln) of xenografts indicated reduced glucose and glutamine uptake in tumors following treatment with CB-839 + erlotinib. Therefore, PET imaging with 18F-FDG and 11C-Gln tracers can be used to non-invasively measure metabolic response to CB-839 and erlotinib combination therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AMPK | |
| 650 | 4 | |a CB-839 | |
| 650 | 4 | |a EGFR | |
| 650 | 4 | |a PET imaging | |
| 650 | 4 | |a erlotinib | |
| 650 | 4 | |a glutamine | |
| 650 | 4 | |a lung cancer | |
| 650 | 4 | |a metabolic crisis | |
| 650 | 7 | |a Benzeneacetamides |2 NLM | |
| 650 | 7 | |a CB-839 |2 NLM | |
| 650 | 7 | |a Carbon Radioisotopes |2 NLM | |
| 650 | 7 | |a Radiopharmaceuticals |2 NLM | |
| 650 | 7 | |a Thiadiazoles |2 NLM | |
| 650 | 7 | |a Glutamine |2 NLM | |
| 650 | 7 | |a 0RH81L854J |2 NLM | |
| 650 | 7 | |a Fluorodeoxyglucose F18 |2 NLM | |
| 650 | 7 | |a 0Z5B2CJX4D |2 NLM | |
| 650 | 7 | |a Erlotinib Hydrochloride |2 NLM | |
| 650 | 7 | |a DA87705X9K |2 NLM | |
| 650 | 7 | |a ErbB Receptors |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a AMP-Activated Protein Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.31 |2 NLM | |
| 650 | 7 | |a Glutaminase |2 NLM | |
| 650 | 7 | |a EC 3.5.1.2 |2 NLM | |
| 700 | 1 | |a Bailey, Sean T |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jason T |e verfasserin |4 aut | |
| 700 | 1 | |a Fishbein, Michael C |e verfasserin |4 aut | |
| 700 | 1 | |a Magyar, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a Braas, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Graeber, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Jackson, Nicholas J |e verfasserin |4 aut | |
| 700 | 1 | |a Czernin, Johannes |e verfasserin |4 aut | |
| 700 | 1 | |a Emberley, Ethan |e verfasserin |4 aut | |
| 700 | 1 | |a Gross, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Janes, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Mackinnon, Andy |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Alison |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez, Mirna |e verfasserin |4 aut | |
| 700 | 1 | |a Works, Melissa |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Winter |e verfasserin |4 aut | |
| 700 | 1 | |a Parlati, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Demo, Susan |e verfasserin |4 aut | |
| 700 | 1 | |a Garon, Edward |e verfasserin |4 aut | |
| 700 | 1 | |a Krysan, Kostyantyn |e verfasserin |4 aut | |
| 700 | 1 | |a Walser, Tonya C |e verfasserin |4 aut | |
| 700 | 1 | |a Dubinett, Steven M |e verfasserin |4 aut | |
| 700 | 1 | |a Sadeghi, Saman |e verfasserin |4 aut | |
| 700 | 1 | |a Christofk, Heather R |e verfasserin |4 aut | |
| 700 | 1 | |a Shackelford, David B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell reports |d 2012 |g 18(2017), 3 vom: 17. Jan., Seite 601-610 |w (DE-627)NLM217067492 |x 2211-1247 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2017 |g number:3 |g day:17 |g month:01 |g pages:601-610 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.celrep.2016.12.061 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2017 |e 3 |b 17 |c 01 |h 601-610 | ||